Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line

Rick Sorensen, BS, Sarah Meadows, Anella Yahiaoui, BS, Li Li, PhD, Peng Yue, PhD, Adam Kashishian, BS, Christophe Queva, PhD, Stacey Tannheimer, PhD

Blood (2015) 126 (23): 2482.

https://doi.org/10.1182/blood.V126.23.2482.2482

Published: 2015

Journal Articles

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Sarah A Meadows, Huong (Marie) Nguyen, M.D., Christophe Queva, PhD, Brian J. Lannutti, PhD, Adam Kashishian, Susie Jun, MD, PhD, Steven E. Coutre, MD, Roger Dansey, MD, Jason Gotlib, MD, MS

Blood (2013) 122 (21): 4065.

https://doi.org/10.1182/blood.V122.21.4065.4065

Published: 2013

Journal Articles

Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival

Thomas Diacovo, MD, Dosh Whye, Evgeni Efimenko, Jianchung Chen, Valeria Tosello, PhD, Kim De Keersmaecker, PhD, Adam Kashishian, Mary Ann Thompson, MD, PhD, Mireia Castillo, MD, Carlos Cordon-Cardo, MD, PhD, Utpal P. Dave, MD, Adolfo A. Ferrando, MD, PhD, Brian J. Lannutti, PhD, Prem Subramaniam

Blood (2012) 120 (21): 1492.

https://doi.org/10.1182/blood.V120.21.1492.1492

Published: 2012

Journal Articles

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

Sarah A. Meadows, Francisco Vega, Adam Kashishian, Dave Johnson, Volker Diehl, Langdon L. Miller, Anas Younes, Brian J. Lannutti

Blood (2012) 119 (8): 1897–1900.

https://doi.org/10.1182/blood-2011-10-386763

Published: 2012

Includes: Supplemental data

Journal Articles

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

Sarah A Meadows, Adam Kashishian, David Johnson, Roger G Ulrich, Langdon L Miller, Brian J. Lannutti, PhD

Blood (2011) 118 (21): 3730.

https://doi.org/10.1182/blood.V118.21.3730.3730

Published: 2011

Journal Articles

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Brian J. Lannutti, Sarah A. Meadows, Sarah E. M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey W. Tyner, Marc M. Loriaux, Mike Deininger, Brian J. Druker, Kamal D. Puri, Roger G. Ulrich, Neill A. Giese

Blood (2011) 117 (2): 591–594.

https://doi.org/10.1182/blood-2010-03-275305

Published: 2011

Includes: Supplemental data

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

Sarah A Meadows, BS, Adam Kashishian, BS, Dave Johnson, Volker Diehl, Brian Lannutti, PhD

Blood (2010) 116 (21): 3926.

https://doi.org/10.1182/blood.V116.21.3926.3926

Published: 2010

Journal Articles

CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment.

Brian J Lannutti, Sarah A Meadows, Adam Kashishian, Bart Steiner, Galina Pogosov, Olga Sala-Torra, Amy J Johnson, John C. Byrd, Jerald Radich, Neill A. Giese

Blood (2009) 114 (22): 286.

https://doi.org/10.1182/blood.V114.22.286.286

Published: 2009

Journal Articles

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

Sarah E. May, Adam Kashishian, Thomas S. Lin, MD, PhD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH, Roger G. Ulrich, PhD, Hao Chen, PhD, Albert S. Yu, MD, PhD, Kamal D. Puri, PhD, BSc, MSc, Brian J. Lannutti, PhD, Neill A. Giese, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2008) 112 (11): 3165.

https://doi.org/10.1182/blood.V112.11.3165.3165

Published: 2008

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Brian J Lannutti, Sarah A. Meadows, Adam Kashishian, Bart Steiner, Sarah May, Amy J. Johnson, Roger G. Ulrich, Albert Yu, Michael W. Gallatin, John C. Byrd, MD, Kamal D. Puri, Neill A. Giese

Blood (2008) 112 (11): 16.

https://doi.org/10.1182/blood.V112.11.16.16

Published: 2008

NARROW

Investigation of the Mechanism of Idelalisib Resistance in the Follicular Lymphoma WSU-Fsccl Cell Line

PI3Kδ Inhibitor Idelalisib Inhibits AKT Signaling In Myelofibrosis Patients On Chronic JAK Inhibitor Therapy

Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival

PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma

CAL-101 (GS-1101), a Specific Inhibitor of Phosphatidylinositol-3-Kinase-Delta (PI3Kδ), Disrupts Signals From the Microenvironment, Induces Apoptosis, and Enhances the Antitumor Activity of Everolimus (RAD001), An Inhibitor of Mammalian Target of Rapamycin (mTOR), in Mantle Cell Lymphoma (MCL),

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

CAL-101, a Potent Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-kinase, Attenuates Pathway Signaling, Induces Apoptosis, and Overcomes Signals From the Microenvironment In Cellular Models of Hodgkin Lymphoma

CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment.

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only